TrialThe journal of prevention of Alzheimer's disease2026

Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension.

Jennifer A Zimmer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.